BioAgilytix, a provider of contract bioanalytical testing services specializing in large molecule bioanalysis, said today it has acquired IPM Biotech for an undisclosed price. BioAgilytix said the deal will combine IPM’s immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) expertise with BioAgilytix’s complementary capabilities in immunogenicity and PK, as well as biomarkers and cell-based assays.
Click for full article
Services
Platforms